Analgesics, Analgesics, Opioid, Anesthesia, Dexmedetomidine, Gabapentin, General Anesthesia, Ketamine, Lidocaine, Narcotics, Obstructive Sleep Apnea of Child, Pathologic Processes, Physiologic Effects of Drugs, Postoperative Complications, Pulse Oximetry, Respiratory Depression, Sleep Disordered Breathing, Tonsillectomy
Conditions
Keywords
Opioid-sparing, Opioid-free
Brief summary
The objective of this trial is to determine whether an opioid-free general anesthetic (OFA) technique utilizing ketamine, dexmedetomidine, lidocaine, and gabapentin can help reduce postoperative respiratory depression in the post-anesthesia care unit and ward in children with sleep-disordered breathing undergoing tonsillectomy when compared with traditional opioid-containing techniques. It is expected that this OFA regimen will have a measurable reduction on postoperative respiratory depression in children with sleep-disordered breathing.
Detailed description
The objective of this trial is to determine whether an opioid-free general anesthetic can help reduce postoperative respiratory depression in the post-anesthesia care unit and ward in children with sleep-disordered breathing undergoing tonsillectomy when compared with traditional opioid-containing techniques.
Interventions
acetaminophen 15 mg/kg, gabapentin 10 mg/kg
acetaminophen 15 mg/kg
Ketamine 0.5 mg/kg, Lidocaine 1 mg/kg, Dexmedetomidine 0.3 mcg/kg
Fentanyl 0.5 mcg/kg, Dexmedetomidine 0.3 mcg/kg
Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg
Sevoflurane (dose titrated to effect)
Sevoflurane (dose titrated to effect), Fentanyl as needed (dose at anesthesiologist's discretion)
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients aged 0-12 years with Sleep Disordered Breathing (SDB) who are scheduled for elective Tonsillectomy/AdenoTonsillectomy (T/AT) will be recruited at Royal University Hospital, Saskatoon, Saskatchewan.
Exclusion criteria
* age \> 12; American Society of Anesthesiologists (ASA) Classification \> IV; significant cardiorespiratory, neurological, craniofacial, hepatic, renal, or genetic disorders, excluding SDB; concomitant surgical procedures other than myringotomy and tubes; and allergy to any of the study drugs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Respiratory depression | 24 hours following surgery | Number of desaturation events (oxygen saturation by pulse oximetry (SPO2) \<90%) as measured by a Masimo Radical-7 pulse oximeter during the first postoperative night's sleep |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quantified opioid consumption | 24 hours following surgery | Quantified opioid consumption |
| Pediatric Agitation Emergence Delirium (PAED) scale | 24 hours following surgery | Pediatric Agitation Emergence Delirium (PAED) scale |
| Face Legs Activity Cry Consolability (FLACC) scale | 24 hours following surgery | Face Legs Activity Cry Consolability (FLACC) scale |
| Time until Post Anesthesia Care Unit (PACU) discharge readiness | 24 hours following surgery | Time until Post Anesthesia Care Unit (PACU) discharge readiness |
| Other adverse effects | 24 hours following surgery | Other adverse effects |
Countries
Canada